Autologous anti-CD19 CAR T-cell therapy composed of defined CD4+ and CD8+ T-cell subsets engineered to target CD19.
Autologous CD4+ and CD8+ T cells engineered with an anti-CD19 chimeric antigen receptor (scFv-4-1BB-CD3zeta). Upon binding CD19 on B-cell malignancies, the CAR triggers T-cell activation, proliferation, cytokine release, and cytotoxic killing of CD19+ cells. The 4-1BB domain enhances persistence and antitumor activity, and a truncated EGFR allows tracking and potential elimination with cetuximab.
Anti-CD19 CAR T cells bind CD19 and directly kill CD19+ cells via T-cell cytotoxic mechanisms (perforin/granzyme-mediated lysis and death-receptor pathways).
Anti-CD20 monoclonal antibody that depletes B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes CD20-positive cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis.
Rituximab binds CD20 and eliminates CD20+ cells via complement-dependent cytotoxicity and Fc-mediated ADCC (NK cells/macrophages), and can also trigger apoptosis upon CD20 crosslinking.
A bispecific T‑cell engager (BiTE) antibody construct that binds CD19 on B cells and CD3 on T cells, redirecting cytotoxic T cells to kill CD19-positive leukemia cells.
Blinatumomab is a bispecific anti-CD19×CD3 antibody that bridges CD19-positive B cells and CD3-positive T cells, activating TCR/CD3 signaling to redirect cytotoxic T cells to kill CD19-expressing leukemia cells via immune synapse formation and perforin/granzyme-mediated lysis.
Blinatumomab links CD19 on target cells to CD3 on T cells, forming an immune synapse and activating T cells to kill CD19+ cells via perforin/granzyme-mediated cytotoxicity.
Investigational immunotherapy drug administered as a short-term intravenous infusion; specific mechanism, target, and modality not disclosed. Studied as monotherapy in a Phase 1 first-in-human dose-escalation and expansion trial for adults with advanced solid tumors.
AMG 305 is a T‑cell–engaging bispecific antibody that binds CD3 on cytotoxic T cells and simultaneously recognizes the tumor-associated antigens cadherin‑3 (CDH3) and mesothelin (MSLN) on tumor cells. By crosslinking T cells to tumor cells co‑expressing CDH3 and MSLN, it activates T‑cell cytotoxicity and promotes selective lysis of dual‑positive tumor cells, improving specificity and limiting activity against normal tissues expressing only one antigen.
AMG 305 is a T‑cell–engaging bispecific that links CD3 on T cells to CDH3 and MSLN on tumor cells, activating T cells to kill dual‑positive cells via perforin/granzyme‑mediated cytolysis; CDH3-only cells are largely spared.
Investigational immunotherapy drug administered as a short-term intravenous infusion; specific mechanism, target, and modality not disclosed. Studied as monotherapy in a Phase 1 first-in-human dose-escalation and expansion trial for adults with advanced solid tumors.
AMG 305 is a T‑cell–engaging bispecific antibody that binds CD3 on cytotoxic T cells and simultaneously recognizes the tumor-associated antigens cadherin‑3 (CDH3) and mesothelin (MSLN) on tumor cells. By crosslinking T cells to tumor cells co‑expressing CDH3 and MSLN, it activates T‑cell cytotoxicity and promotes selective lysis of dual‑positive tumor cells, improving specificity and limiting activity against normal tissues expressing only one antigen.
AMG 305 crosslinks CD3 on T cells to mesothelin and CDH3 on tumor cells, activating T-cell cytotoxicity (perforin/granzyme) to lyse cells co-expressing mesothelin and CDH3.